Skip to main content

SELLAS Life Sciences Group, Inc.

corporate_fare Company Profile

SELLAS Life Sciences Group, Inc.

SLS·NASDAQ·Life Sciences·CIK 0001390478

We are a late-stage clinical biopharmaceutical company focused on developing new treatments for various cancer types. Our main product candidates are galinpepimut-S (GPS) and SLS009 (tambiciclib). GPS is a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, licensed from Memorial Sloan Kettering Cancer Center. The WT1 protein is found in 20 or more cancer types. GPS is designed to work as a standalone treatment or in combination with other immunotherapies for blood cancers and solid tumors. We are conducting an open-label, randomized Phase 3 clinical trial, called the REGAL study, for GPS as a monotherapy. This study involves patients with acute myeloid leukemia (AML) in the maintenance setting after achieving second complete remission (CR2) following second-line antileukemic therapy. Patients are randomly assigned to receive either GPS or best available treatment (BAT). The REGAL study's primary goal is to measure overall survival (OS). We planned to enroll approximately 125 to 140 patients across about 95 clinical sites in North America, Europe, and Asia. An interim analysis for safety, efficacy, and futility was planned after 60 events (deaths). Enrollment for the study was completed in March 2024. In December 2024, the pre-specified threshold of 60 events (deaths) was reached, initiating the interim analysis by the Independent Data Monitoring Committee (IDMC). In January 2025, the IDMC completed its interim analysis and recommended that the study continue without changes. Our second product candidate, SLS009 (tambiciclib), is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for SLS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders to Vote on Significant Increase in Equity Incentive Plan Shares
  • SELLAS Life Sciences Establishes $150M At-The-Market Equity Offering Program
  • SELLAS Life Sciences Reports Strong Cash Position and Imminent Phase 3 Trial Results
  • SELLAS Life Sciences Reports Strong Liquidity & Positive Clinical Progress for SLS009, Addressing Going Concern
  • SELLAS Life Sciences Secures $42.6M from Warrant Exercises, Boosting Liquidity

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$26.86M
Diluted EPS
-$0.25
Op. Cash Flow
-$28.39M
Operating Income
-$28.27M
Cash & Equivalents
$71.79M
Debt / Equity
0.00×
Shares Outstanding
153.1M sh
Source: 10-K · filed 2026-03-19 · accession 0001390478-26-000003
$14.21 +4.03% today
52-week range · as of 2026-11-12 $1.39 – $15.88
Market cap
$2.78B
Volume
15.5M (1.2× avg)
3-mo avg 13.4M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLS - Filings & News (Page 2)

SLS
Apr 23, 2026, 4:10 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $4.66
Real-time Price: $14.21 info
Change: +$9.55 (+205%) info
Market Cap: $2.785B info
SLS
Mar 20, 2026, 5:01 PM EDT
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $14.21 info
Change: +$9.35 (+192%) info
Market Cap: $2.785B info
SLS
Mar 19, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.23
Real-time Price: $14.21 info
Change: +$8.98 (+172%) info
Market Cap: $2.785B info
SLS
Mar 19, 2026, 4:00 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.23
Real-time Price: $14.21 info
Change: +$8.98 (+172%) info
Market Cap: $2.785B info
SLS
Mar 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.50
Real-time Price: $14.21 info
Change: +$8.71 (+158%) info
Market Cap: $2.785B info
SLS
Jan 08, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $14.21 info
Change: +$10.21 (+255%) info
Market Cap: $2.785B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets